Latest News for: vegf

Edit

Memento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF ...

The Daily Record - Dunn 19 Jun 2026
Lead program, MMT-205, licensed from MabTics Co., Ltd / Curacle Co., Ltd. is a potential best-in-class bispecific ....
Edit

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

PR Newswire 11 Jun 2026
PD-1+VEGF Combinations, with Low CTLA-4-Related Toxicity and Favorable Tolerability ... The overall safety profile is comparable to that of PD-1/VEGF bispecific antibodies, while VEGF-related toxicity appears substantially lower.
Edit

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target ...

My Horry News 01 Jun 2026
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups ....
Edit

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

PR Newswire 01 Jun 2026
Among heavily pretreated patients with advanced solid tumors, Grade ≥3 treatment‑related adverse events (TRAE) occurred in 24.6% of patients, immune‑related adverse events (irAE) in 12.7% , and TRAE possibly related to anti-VEGF in 5.1%.
Edit

Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight

PR Newswire 27 May 2026
... care, by allowing the eye to generate its own anti-VEGF proteins ... Wet AMD Market Analysis Intravitreal anti-VEGF therapy remains the primary treatment approach for wet age-related macular degeneration.
Edit

Vegfed signs Rs100-crore deals to boost Bihar vegetable market

The Times of India 25 May 2026
... opportunities for vegetable growers, the Bihar State Vegetable Processing and Marketing Cooperative Federation Limited (Vegfed) organised a state-level buyer-seller conference in Patna on Monday.
Edit

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting (Crescent Biopharma Inc)

Public Technologies 21 May 2026
"CR-001 is designed to serve as an immuno-oncology backbone and best-in-class PD-1 x VEGF bispecific antibody for people living with cancer," said Ellie Im, M.D., chief medical officer of Crescent.
Edit

Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody

Floyd County Chronicle 13 May 2026
CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan ...
Edit

VEGF-D-induced intraosseous lymphangiogenesis drives site-specific heterotopic bone resorption

PNAS 05 May 2026
.
Edit

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ...

Killeen Daily Herald 21 Apr 2026
SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX. 1877; ....
  • 1

Article Search

tools
×
×
×
×